HUP0402506A2 - FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére - Google Patents

FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére

Info

Publication number
HUP0402506A2
HUP0402506A2 HU0402506A HUP0402506A HUP0402506A2 HU P0402506 A2 HUP0402506 A2 HU P0402506A2 HU 0402506 A HU0402506 A HU 0402506A HU P0402506 A HUP0402506 A HU P0402506A HU P0402506 A2 HUP0402506 A2 HU P0402506A2
Authority
HU
Hungary
Prior art keywords
diabetes
treatment
combination
insulin sensitizers
fbpase inhibitors
Prior art date
Application number
HU0402506A
Other languages
English (en)
Inventor
Mark D. Erion
Paul Poelje
Original Assignee
Metabasis Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics, Inc. filed Critical Metabasis Therapeutics, Inc.
Publication of HUP0402506A2 publication Critical patent/HUP0402506A2/hu
Publication of HUP0402506A3 publication Critical patent/HUP0402506A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A találmány tárgyát kombinált gyógyszerkészítmények képezik, amelyekegy FBPáz inhibitort és egy inzulinérzékenység-fokozó vegyületettartalmaznak. A találmány továbbá ezeknek a vegyületeknek azalkalmazására is vonatkozik diabétesz és a megnövekedett glikémiáskontrollért, az inzulin-érzékenység fokozódásáért, az inzulinszintekcsökkenéséért vagy az inzulinkiválasztás megnövekedéséért felelősbetegségek kezelésére szolgáló gyógyszerkészítmények előállításában. Ó
HU0402506A 1998-12-24 1999-12-22 A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes HUP0402506A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24
PCT/US1999/030713 WO2000038666A2 (en) 1998-12-24 1999-12-22 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number Publication Date
HUP0402506A2 true HUP0402506A2 (hu) 2005-04-28
HUP0402506A3 HUP0402506A3 (en) 2007-05-29

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402506A HUP0402506A3 (en) 1998-12-24 1999-12-22 A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes

Country Status (25)

Country Link
EP (1) EP1143955B1 (hu)
JP (1) JP2003515523A (hu)
KR (3) KR20070046210A (hu)
CN (3) CN100352505C (hu)
AT (1) ATE300288T1 (hu)
AU (1) AU771039B2 (hu)
BR (1) BR9917005A (hu)
CA (1) CA2354053A1 (hu)
CZ (1) CZ20012353A3 (hu)
DE (1) DE69926400T2 (hu)
DK (1) DK1143955T3 (hu)
ES (1) ES2246586T3 (hu)
HK (1) HK1046863B (hu)
HU (1) HUP0402506A3 (hu)
ID (1) ID30237A (hu)
IL (2) IL143569A0 (hu)
MX (1) MXPA01006511A (hu)
NO (1) NO20013115L (hu)
NZ (1) NZ512219A (hu)
PL (1) PL352756A1 (hu)
PT (1) PT1143955E (hu)
RU (2) RU2227749C2 (hu)
SK (1) SK9172001A3 (hu)
WO (1) WO2000038666A2 (hu)
ZA (1) ZA200105016B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
HUP0103143A3 (en) 1998-09-09 2003-01-28 Metabasis Therapeutics Inc San Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase, process for their preparation and their use
CN100595204C (zh) * 1999-12-22 2010-03-24 症变治疗公司 双氨基化膦酸酯前药
CA2401706A1 (en) 2000-03-08 2001-09-13 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
RU2328308C2 (ru) * 2000-07-06 2008-07-10 Метабэйсис Терапьютикс, Инк. Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета
EP1340749A4 (en) 2000-11-17 2007-09-05 Takeda Pharmaceutical isoxazole
NZ536328A (en) 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
JP4332496B2 (ja) 2002-05-13 2009-09-16 メタバシス・セラピューティクス・インコーポレイテッド Pmeaおよびpmpa環生成合成
EP1534314B1 (en) * 2002-09-04 2014-10-22 DSM IP Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
JP4921162B2 (ja) * 2003-02-11 2012-04-25 ヴァーナリス(ケンブリッジ)リミテッド 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類
HUE025659T2 (hu) 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Tiazol-származék
EP1778250A2 (en) * 2004-08-18 2007-05-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
CN101119748A (zh) * 2004-12-13 2008-02-06 第一三共株式会社 用于治疗糖尿病的药物组合物
CA2591416A1 (en) * 2004-12-15 2006-06-22 Daiichi Sankyo Company Limited Medicinal composition containing fbpase inhibitor
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
JPWO2006137527A1 (ja) 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びage生成阻害剤
CA2008325A1 (en) * 1989-01-24 1990-07-24 Harry E. Gruber Method and compounds for aica riboside delivery and for lowering blood glucose
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase

Also Published As

Publication number Publication date
IL143569A0 (en) 2002-04-21
KR100689943B1 (ko) 2007-03-08
PL352756A1 (en) 2003-09-08
ES2246586T3 (es) 2006-02-16
DE69926400D1 (de) 2005-09-01
CN1714866A (zh) 2006-01-04
AU2058300A (en) 2000-07-31
NO20013115L (no) 2001-08-24
CZ20012353A3 (cs) 2001-12-12
WO2000038666A2 (en) 2000-07-06
EP1143955A3 (en) 2002-08-28
EP1143955A2 (en) 2001-10-17
CN100352505C (zh) 2007-12-05
ZA200105016B (en) 2002-09-19
NZ512219A (en) 2004-12-24
HK1046863B (zh) 2008-07-25
MXPA01006511A (es) 2004-03-19
AU771039B2 (en) 2004-03-11
ID30237A (id) 2001-11-15
SK9172001A3 (en) 2002-04-04
CA2354053A1 (en) 2000-07-06
PT1143955E (pt) 2005-11-30
CN101164618A (zh) 2008-04-23
WO2000038666A3 (en) 2001-11-29
CN1350466A (zh) 2002-05-22
HK1046863A1 (en) 2003-01-30
ATE300288T1 (de) 2005-08-15
JP2003515523A (ja) 2003-05-07
KR20060114724A (ko) 2006-11-07
RU2227749C2 (ru) 2004-04-27
RU2003132054A (ru) 2005-04-20
HUP0402506A3 (en) 2007-05-29
KR20010099942A (ko) 2001-11-09
IL143569A (en) 2006-06-11
DK1143955T3 (da) 2005-11-14
DE69926400T2 (de) 2006-05-24
NO20013115D0 (no) 2001-06-21
KR20070046210A (ko) 2007-05-02
EP1143955B1 (en) 2005-07-27
BR9917005A (pt) 2002-04-02

Similar Documents

Publication Publication Date Title
HUP0402506A2 (hu) FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
NO306725B1 (no) Ny krystallmodifikasjon av CDCH, fremgangsmate for fremstilling derav og farmasoytiske preparater inneholdende denne samt anvendelse av forbindelsen for fremstilling av legemidler
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
SE9800836D0 (sv) New Compounds
HUP0401501A2 (hu) Érrendszeri gyulladás kezelése vagy megelőzése szterin-felszívódást gátló anyagokat tartalmazó gyógyszerkészítmények alkalmazásával
DE60110054D1 (en) Cardioprotektive phosphonate
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
GB9924957D0 (en) Novel treatment
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
HUP0204097A2 (hu) Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HUP0402061A2 (hu) Rosszindulatú daganatok kezelésére alkalmas, egy biszfoszfonát, egy COX-2 inhibitor és egy taxol kombinációját tartalmazó gyógyszerkészítmények
AU2003255429A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
ATE262343T1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie
WO2004047854A3 (en) Methods for the treatment of alzheimers disease and compositions therefore
WO2002023784A3 (en) Cysteine protease inhibitors
WO2003086461A3 (de) Verwendung von substanzen zur behandlung von tumoren

Legal Events

Date Code Title Description
NF4A Restoration of patent protection
FD9A Lapse of provisional protection due to non-payment of fees